{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:44:32Z","timestamp":1761518672686,"version":"3.41.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1998,5,1]],"date-time":"1998-05-01T00:00:00Z","timestamp":893980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1998,5,1]],"date-time":"1998-05-01T00:00:00Z","timestamp":893980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[1998,5]]},"DOI":"10.1023\/a:1006059211817","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T00:38:24Z","timestamp":1040517504000},"page":"129-134","source":"Crossref","is-referenced-by-count":19,"title":["Epirubicin\/vinorelbine as first line therapy in metastatic breast cancer"],"prefix":"10.1007","volume":"49","author":[{"given":"Editta","family":"Baldini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Tibaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Chiavacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Di","family":"Lieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Fioretto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalia","family":"Giallombardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Taviani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Ghezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Bolognini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierfranco","family":"Conte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"162890_CR1","first-page":"604","volume-title":"Breast Disease","author":"IC Henderson","year":"1991","unstructured":"Henderson IC: Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Disease, 2nd ed. J.B. Lippincott, Philadelphia, 1991, pp 604\u2013665","edition":"2nd ed."},{"key":"162890_CR2","first-page":"17","volume":"44","author":"HT Mourisden","year":"1992","unstructured":"Mourisden HT: Systemic therapy of metastatic breast cancer. Drugs 44: 17\u201328, 1992","journal-title":"Drugs"},{"key":"162890_CR3","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","volume":"13","author":"L Gianni","year":"1995","unstructured":"Gianni L, Munzone E, Capri G: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688\u20132699, 1995","journal-title":"J Clin Oncol"},{"key":"162890_CR4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/oxfordjournals.annonc.a010717","volume":"7","author":"J Gehl","year":"1996","unstructured":"Gehl J, Boesgaard M, Paaske T, Vittrup Jensen B, Dombernowsky P: Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 7: 687\u2013693, 1996","journal-title":"Ann Oncol"},{"key":"162890_CR5","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.1997.15.7.2510","volume":"15","author":"PF Conte","year":"1997","unstructured":"Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi C, Danesi R: Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours; a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 15: 2510\u20132517, 1997","journal-title":"J Clin Oncol"},{"key":"162890_CR6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JCO.1994.12.1.37","volume":"12","author":"LJ Ayash","year":"1994","unstructured":"Ayash LJ, Elias A, Wheeler C: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 12: 37\u201344, 1994","journal-title":"J Clin Oncol"},{"key":"162890_CR7","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1995.13.10.2483","volume":"13","author":"WR Bezwoda","year":"1995","unstructured":"Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 13: 2483\u20132489, 1995","journal-title":"J Clin Oncol"},{"key":"162890_CR8","first-page":"121","volume":"149","author":"WP Peters","year":"1996","unstructured":"Peters WP, Jones RB, Vredenbourg J et al.: A large prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin based induction therapy (AFM). Proc Am Soc Oncol (abstr) 149: 121, 1996","journal-title":"Proc Am Soc Oncol"},{"issue":"4","key":"162890_CR9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2165\/00003495-199200444-00005","volume":"44","author":"E Cvitkovic","year":"1992","unstructured":"Cvitkovic E, Izzo J: The current and future place of vinorelbine in cancer therapy. Drugs 44(4): 36\u201345, 1992","journal-title":"Drugs"},{"key":"162890_CR10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0304-3835(85)90186-7","volume":"27","author":"G Mathe","year":"1985","unstructured":"Mathe G, Reizensten P: Phase I pharmacology study of a new vinca-alkaloid: Navelbine. Cancer Lett 27: 285\u2013293, 1985","journal-title":"Cancer Lett"},{"key":"162890_CR11","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1993.11.7.1245","volume":"11","author":"P Fumoleau","year":"1993","unstructured":"Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M: Phase II trial of weekly intravenous vinorelbine in first line advanced breast cancer chemotherapy. J Clin Oncol 11: 1245\u20131252, 1993","journal-title":"J Clin Oncol"},{"key":"162890_CR12","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/oxfordjournals.annonc.a059019","volume":"5","author":"J Garcia-Conde","year":"1994","unstructured":"Garcia-Conde J, Lluch A, Martin M: Phase II study of Navelbine in advanced breast cancer. Ann Oncol 5: 854\u2013857, 1994","journal-title":"Ann Oncol"},{"key":"162890_CR13","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1200\/JCO.1994.12.9.1764","volume":"12","author":"M Spielmann","year":"1994","unstructured":"Spielmann M, Dorval T, Turpin F, Antoine E, Jouve M, Maylevin F, Lacombe D, Rouesse J, Pouillart P, Tursz T, Merle S: Phase II trial of vinorclbinc\/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 12: 1764\u20131770, 1994","journal-title":"J Clin Oncol"},{"key":"162890_CR14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.1988.6.4.679","volume":"6","author":"French Epirubicin Study Group","year":"1988","unstructured":"French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 6: 679\u2013688, 1988","journal-title":"J Clin Oncol"},{"key":"162890_CR15","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.1988.6.6.976","volume":"6","author":"Italian Multicenter Breast Study with Epirubicin","year":"1988","unstructured":"Italian Multicenter Breast Study with Epirubicin: Phase III randomized study of fluorouracil, epirubicin and cyclophosphamide vs fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer. J Clin Oncol 6: 976\u2013982, 1988","journal-title":"J Clin Oncol"},{"key":"162890_CR16","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.1996.14.4.1146","volume":"14","author":"L Bastholt","year":"1996","unstructured":"Bastholt L, Dalmark M, Gjedde SB, Pfeiffer P, Pedersen D, Sandberg E, Kjaer M, Mourisden HT, Rose C, Nielsen OS, Jakobsen P, Bentzen SM: Dose-response relationship of epirubicm in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14: 1146\u20131155, 1996","journal-title":"J Clin Oncol"},{"key":"162890_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R: Optimal two stage design for phase II clinial trials. Controlled Clin Trials 10: 1\u201310, 1989","journal-title":"Controlled Clin Trials"},{"key":"162890_CR18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P: Non parametric estimation from incomplete observation. J Am Stat Assoc 53: 457\u2013481, 1958","journal-title":"J Am Stat Assoc"},{"key":"162890_CR19","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.1996.14.8.2197","volume":"14","author":"PAC Greenberg","year":"1996","unstructured":"Greenberg PAC, Hortobagyi G, Smith TL: Long term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197\u20132205, 1996","journal-title":"J Clin Oncol"},{"key":"162890_CR20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1200\/JCO.1996.14.3.764","volume":"14","author":"M Venturini","year":"1996","unstructured":"Venturini M, Bruzzi P, Del Mastro L, Garrone O, Bertelli G, Guelfi M, Pastorino S, Rosso R, Sertoli MR: Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epirubicin, and fluorouracil in patients with metastatic breast cancer. J Clin Oncol 14: 764\u2013773, 1996","journal-title":"J Clin Oncol"},{"key":"162890_CR21","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1016\/0959-8049(95)00416-5","volume":"31","author":"C Blomqvist","year":"1995","unstructured":"Blomqvist C, Hietanen P, Teerenhovi L, Rissanen P: Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study. Eur J Cancer 31: 2406\u20132408, 1995","journal-title":"Eur J Cancer"},{"key":"162890_CR22","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/0959-8049(93)90114-U","volume":"12","author":"C Gridelli","year":"1993","unstructured":"Gridelli C, De Placido S, Pepe R: Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small-cell lung cancer. Eur J Cancer 12: 1729\u20131731, 1993","journal-title":"Eur J Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006059211817.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1006059211817\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1023\/A:1006059211817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006059211817.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:05:40Z","timestamp":1750478740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1006059211817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,5]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1998,5]]}},"alternative-id":["162890"],"URL":"https:\/\/doi.org\/10.1023\/a:1006059211817","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[1998,5]]}}}